Content area
Full Text
[Image omitted] - (http://www.fiercebiotech.com/story/dunsire-makes-quick-leap-millennium-fast-growing-envivo/2013-07-11)
Deborah Dunsire
Deborah Dunsire's "retirement" didn't last long. Just two months after abruptly leaving Millennium (http://www.fiercebiotech.com/special-reports/top-10-women-biotech) as Takeda prepared to absorb its R&D work in its global research group and eliminate her position, Dunsire has been tapped as the new CEO at EnVivo Pharmaceuticals , a fast-growing drug developer in Watertown, MA, focused on a late-stage CNS program for Alzheimer's and schizophrenia .
Dunsire had a high profile during her 8-year stint as CEO of Millennium, which Takeda acquired for $8.8 billion. But she says moving to the much smaller biotech--with about 130 employees--presents plenty of big challenges. By the end of this year, she says, the staff is expected to swell to 150 as it advances not just the late-stage work but a pipeline that includes three other clinical-stage drugs...